BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2025-08
189 industry Phase 2/3 trial readout(s) and 34 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2025-08-01 | FDA approval | approved | BRACCO | E-Z-DISK | Approved 2025-08-01: E-Z-DISK (NDA219840 ORIG1) |
| 2025-08-01 | FDA approval | approved | HANDA THERAP | PHYRAGO | Approved 2025-08-01: PHYRAGO (NDA216099 SUPPL5) |
| 2025-08-05 | Complete response letter | complete response | Accord BioPharma, Inc. | CRL 2025-08-05: Accord BioPharma, Inc. BLA 761147 | |
| 2025-08-05 | FDA approval | approved | TEVA PHARMS USA | AJOVY | Approved 2025-08-05: AJOVY (BLA761089 SUPPL31) |
| 2025-08-06 | Complete response letter | complete response | Immedica Pharma AB | CRL 2025-08-06: Immedica Pharma AB BLA 761211 | |
| 2025-08-06 | FDA approval | approved | CHIMERIX | MODEYSO | Approved 2025-08-06: MODEYSO (NDA219876 ORIG1) |
| 2025-08-08 | FDA approval | approved | AVYXA HOLDINGS | KYXATA | Approved 2025-08-08: KYXATA (NDA219921 ORIG1) |
| 2025-08-08 | FDA approval | approved | GENENTECH | ACTEMRA | Approved 2025-08-08: ACTEMRA (BLA125276 SUPPL149) |
| 2025-08-08 | FDA approval | approved | BOEHRINGER INGELHEIM | HERNEXEOS | Approved 2025-08-08: HERNEXEOS (NDA219042 ORIG1) |
| 2025-08-12 | FDA approval | approved | INSMED INC INSM | BRINSUPRI | Approved 2025-08-12: BRINSUPRI (NDA217673 ORIG1) |
| 2025-08-13 | FDA AdCom | held | AdCom 2025-08-13: General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee | ||
| 2025-08-14 | FDA approval | approved | JANSSEN BIOTECH | RYBREVANT | Approved 2025-08-14: RYBREVANT (BLA761210 SUPPL9) |
| 2025-08-14 | FDA approval | approved | JANSSEN BIOTECH | LAZCLUZE | Approved 2025-08-14: LAZCLUZE (NDA219008 SUPPL2) |
| 2025-08-15 | FDA approval | approved | TONIX TNXP | TONMYA | Approved 2025-08-15: TONMYA (NDA219428 ORIG1) |
| 2025-08-15 | FDA approval | approved | NOVO NVO | WEGOVY WEGOVY FLEXTOUCH WEGOVY HD | Approved 2025-08-15: WEGOVY; WEGOVY FLEXTOUCH; WEGOVY HD (NDA215256 SUPPL24) |
| 2025-08-15 | FDA approval | approved | THEA PHARMA | CYKLX | Approved 2025-08-15: CYKLX (NDA218643 ORIG1) |
| 2025-08-18 | Complete response letter | complete response | PTC Therapeutics, Inc. PTC | vatiquinone in the treatment of Friedreich’s Ataxia (FA) | CRL 2025-08-18: PTC Therapeutics, Inc. NDA 220049 (vatiquinone in the treatment of Friedreich’s Ataxia (FA)) |
| 2025-08-18 | FDA approval | approved | Lundbeck Seattle BioPharmaceuticals, Inc. | VYEPTI | Approved 2025-08-18: VYEPTI (BLA761119 SUPPL10) |
| 2025-08-21 | FDA approval | approved | IONIS PHARMS INC IONS | DAWNZERA (AUTOINJECTOR) | Approved 2025-08-21: DAWNZERA (AUTOINJECTOR) (NDA219407 ORIG1) |
| 2025-08-25 | FDA approval | approved | ACCORD | CAMCEVI ETM | Approved 2025-08-25: CAMCEVI ETM (NDA219745 ORIG1) |
| 2025-08-25 | FDA approval | approved | HIKMA | KLOXXADO | Approved 2025-08-25: KLOXXADO (NDA212045 SUPPL5) |
| 2025-08-27 | Complete response letter | complete response | Vyluma, Inc. | atropine sulphate ophthalmic solution, 0 | CRL 2025-08-27: Vyluma, Inc. NDA 217711 (atropine sulphate ophthalmic solution, 0) |
| 2025-08-27 | Complete response letter | complete response | Outlook Therapeutics, Inc. OTLK | CRL 2025-08-27: Outlook Therapeutics, Inc. BLA 761320 | |
| 2025-08-27 | Complete response letter | complete response | Saol International Development Limited | sodium dichloroacetate | CRL 2025-08-27: Saol International Development Limited NDA 218679 (sodium dichloroacetate) |
| 2025-08-27 | FDA approval | approved | DAY ONE BIOPHARMS | OJEMDA | Approved 2025-08-27: OJEMDA (NDA218033 SUPPL2) |
| 2025-08-27 | FDA approval | approved | TRAVERE TVTX | FILSPARI | Approved 2025-08-27: FILSPARI (NDA216403 SUPPL5) |
| 2025-08-27 | FDA approval | approved | DAY ONE BIOPHARMS | OJEMDA | Approved 2025-08-27: OJEMDA (NDA217700 SUPPL2) |
| 2025-08-28 | FDA approval | approved | XTM CONSULTING | LOPRESSOR | Approved 2025-08-28: LOPRESSOR (NDA218698 ORIG1) |
| 2025-08-29 | FDA approval | approved | EISAI INC | LEQEMBI IQLIK | Approved 2025-08-29: LEQEMBI IQLIK (BLA761375 ORIG1) |
| 2025-08-29 | FDA approval | approved | SHANGHAI HENLIUS BIOTECH | BILDYOS; BILPREVDA | Approved 2025-08-29: BILDYOS; BILPREVDA (BLA761444 ORIG1) |
| 2025-08-29 | FDA approval | approved | AMGEN INC AMGN | OTEZLA; OTEZLA XR | Approved 2025-08-29: OTEZLA; OTEZLA XR (NDA210745 ORIG2) |
| 2025-08-29 | FDA approval | approved | AMGEN INC AMGN | OTEZLA; OTEZLA XR | Approved 2025-08-29: OTEZLA; OTEZLA XR (NDA210745 ORIG1) |
| 2025-08-29 | FDA approval | approved | ALMATICA | ESCITALOPRAM | Approved 2025-08-29: ESCITALOPRAM (NDA219130 ORIG1) |
| 2025-08-29 | FDA approval | approved | GENZYME CORP | WAYRILZ | Approved 2025-08-29: WAYRILZ (NDA219685 ORIG1) |
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2025-08 est. | P2 | Medeor Therapeutics, Inc. | NCT03606746 Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants | Kidney Transplant Rejection | withdrawn | |
| 2025-08 est. | P1/P2 | Editas Medicine, Inc. EDIT | NCT04853576 A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY) | Sickle Cell Disease; Hemoglobinopathies | active not recruiting | 45 |
| 2025-08 est. | P2 | Philips Portuguesa S.A. | NCT04903951 Impact of Early Ventilation in Stroke Outcomes in Patients With Sleep Apnea After First Ever Stroke | Stroke; Sleep Apnea | unknown | 90 |
| 2025-08 est. | P1/P2 | Smart Immune SAS | NCT04959903 Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT | Hematological Malignancies | recruiting | 36 |
| 2025-08 est. | P1/P2 | Glaukos Corporation GKOS | NCT05314738 Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus | Progressive Keratoconus | unknown | 150 |
| 2025-08 est. | P1/P2 | Cyclacel Pharmaceuticals, Inc. | NCT05358379 A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Solid Tumor, Adult Lymphoma | unknown | 330 |
| 2025-08 est. | P3 | Radius Pharmaceuticals, Inc. RDUFF | NCT05387798 A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome | Prader-Willi Syndrome | withdrawn | |
| 2025-08 est. | P3 | R-Pharm International, LLC | NCT05432960 Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD) | Adult-Onset Still's Disease; AOSD | withdrawn | |
| 2025-08 est. | P1/P2 | Guangzhou Jiayin Biotech Ltd | NCT05614531 Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1 | Spinal Muscular Atrophy Type I | unknown | 12 |
| 2025-08 est. | P1/P2 | Selecta Biosciences, Inc. | NCT05778877 A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA | Methylmalonic Acidemia (MMA) | withdrawn | |
| 2025-08 est. | P2/P3 | Kartos Therapeutics, Inc. | NCT05797831 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | Endometrial Cancer | recruiting | 268 |
| 2025-08 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05922345 Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer P | Non-small Cell Lung Cancer | unknown | 518 |
| 2025-08 est. | P2 | Melius Pharma AB | NCT05983471 Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF) | Idiopathic Pulmonary Fibrosis; Cough; IPF; Fibrotic Lung Disease; Chronic Cough; Coughing | active not recruiting | 40 |
| 2025-08 est. | P2 | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | NCT06040346 Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum | Malaria | unknown | 60 |
| 2025-08 est. | P3 | Faes Farma, S.A. | NCT06176560 Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis. | Colitis, Ulcerative | unknown | 376 |
| 2025-08 est. | P3 | HanAll BioPharma Co., Ltd. | NCT06400589 A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease | Dry Eye | suspended | 750 |
| 2025-08 est. | P2 | EyebioKorea, Inc. | NCT06487039 Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration | Neovascular Age-related Macular Degeneration (nAMD) | unknown | 50 |
| 2025-08 est. | P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06522828 A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients | Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer | unknown | 80 |
| 2025-08 est. | P3 | Ache Laboratorios Farmaceuticos S.A. | NCT06577077 Efficacy/ Safety of Product CM9241GRU in Patients With Perennial Allergic Rhinitis | Rhinitis, Allergic, Perennial | unknown | 432 |
| 2025-08 est. | P3 | Shandong New Time Pharmaceutical Co., LTD | NCT06819774 Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute Urticaria | Acute Urticaria | recruiting | 284 |
| 2025-08 est. | P2 | Wellizen Australia | NCT06963840 Effect of Theronomic Ova-All Care on Biomarkers of Ovarian Health in Adult Female With Polycystic Ovarian Syndrome | Polycystic Ovarian Syndrome (PCOS) | active not recruiting | 16 |
| 2025-08 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06981988 A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL | Relapsed/Refractory Indolent NHL | not yet recruiting | 80 |
| 2025-08 est. | P2/P3 | AgelessRx | NCT07092618 Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation | Longevity; GLP-1; Geroscience; Aging | recruiting | 150 |
| 2025-08-01 | P1/P2 | Grifols Therapeutics LLC GRFS | NCT04722887 A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants Wit | Alpha1-Antitrypsin Deficiency | completed | 17 |
| 2025-08-01 | P3 | Janssen Research & Development, LLC | NCT05083169 A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumuma | Multiple Myeloma | active not recruiting | 587 |
| 2025-08-01 | P2 | Sparrow Pharmaceuticals | NCT05307328 SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome | Cushing's Syndrome I; Cushing Disease Due to Increased ACTH Secretion; Cortisol Excess; Cortisol; Hy | completed | 26 |
| 2025-08-01 est. | P2/P3 | Shandong New Time Pharmaceutical Co., LTD | NCT05408221 the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma | Hepatocellular Carcinoma | unknown | 576 |
| 2025-08-01 est. | P1/P2 | Shanghai Huaota Biopharmaceutical Co., Ltd. | NCT05417321 A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors | Advanced Solid Tumor; NSCLC | recruiting | 80 |
| 2025-08-01 est. | P1/P2 | BioSight Ltd. | NCT05503355 A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML | AML, Adult | unknown | 80 |
| 2025-08-01 | P2 | Bristol-Myers Squibb BMY | NCT05567458 A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia. | Beta-thalassemia | active not recruiting | 94 |
| 2025-08-01 | P3 | Chemo Research | NCT06019533 A Trial of Efficacy, Safety and Tolerability of LVDS (Levonorgestrel Vaginal Delivery System) During 13 Cycles | Contraception | completed | 1039 |
| 2025-08-01 est. | P2 | Beijing Tide Pharmaceutical Co., Ltd | NCT06102083 A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | unknown | 120 |
| 2025-08-01 est. | P1/P2 | Frontera Therapeutics | NCT06492850 Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa | X-Linked Retinitis Pigmentosa (XLRP) | unknown | 32 |
| 2025-08-01 est. | P2 | CSPC Ouyi Pharmaceutical Co., Ltd. | NCT06511739 A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients | Non-segmental Vitiligo | unknown | 144 |
| 2025-08-01 | P3 | Zhejiang Kanova Biopharmaceutical Co., LTD | NCT07498634 Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS | Phase III | completed | 323 |
| 2025-08-02 est. | P1/P2 | Betta Pharmaceuticals Co., Ltd. | NCT05869240 BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors | Solid Tumor | unknown | 388 |
| 2025-08-04 | P3 | Belite Bio, Inc BLTE | NCT05244304 Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease | Stargardt Disease 1 | completed | 104 |
| 2025-08-04 | P3 | Bristol-Myers Squibb BMY | NCT05625399 A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma | Melanoma | active not recruiting | 579 |
| 2025-08-04 | P2 | TriGemX Bio, Inc. | NCT06848075 A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine | Migraine | completed | 431 |
| 2025-08-05 | P2 | Merck Sharp & Dohme LLC MRK | NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | Uterine Cervical Neoplasms; Endometrial Neoplasms; Squamous Cell Carcinoma of Head and Neck; Gallbla | completed | 611 |
| 2025-08-05 | P2 | GlaxoSmithKline | NCT05276297 A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chro | Hepatitis B, Chronic | completed | 174 |
| 2025-08-05 | P3 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT05526222 A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis | Atopic Dermatitis | completed | 443 |
| 2025-08-05 | P3 | Pathalys Pharma | NCT05836220 Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 | Secondary Hyperparathyroidism; End Stage Kidney Disease | completed | 412 |
| 2025-08-05 est. | P3 | Akeso | NCT05990127 A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer | Locally Advanced or Metastatic NSCLC | not yet recruiting | 642 |
| 2025-08-05 | P1/P2 | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | NCT06703203 Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine | Pneumococcal Vaccines | completed | 450 |
| 2025-08-05 | P3 | Gan & Lee Pharmaceuticals. | NCT06780410 A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid | Primary Hyperlipidemia | completed | 245 |
| 2025-08-05 | P1/P2 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | NCT06824519 Clinical Trials of Quadrivalent Influenza Vaccine | Influenza, Human | recruiting | 620 |
| 2025-08-06 | P3 | Stallergenes Greer | NCT05668390 Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma | Allergic Rhinoconjunctivitis; Birch Pollen Allergy | completed | 553 |
| 2025-08-06 | P2 | Sanofi SNY | NCT05856331 Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema | Alpha 1-Antitrypsin Deficiency; Emphysema | completed | 99 |
| 2025-08-06 | P3 | Incyte Biosciences Japan GK INCY | NCT06263478 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Gr | Chronic Graft-versus-host-disease | active not recruiting | 21 |
| 2025-08-07 | P1/P2 | Hoffmann-La Roche | NCT03677154 Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Mo | Diffuse Large B-cell Lymphoma | completed | 188 |
| 2025-08-07 | P1/P2 | Heron Neutron Medical Corp. | NCT06668987 A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma | Meningioma; Boron Neutron Capture Therapy | completed | 10 |
| 2025-08-07 | P2 | Nanjing Minova Pharmaceutical Co., Ltd. | NCT06963580 Efficacy of MI078 Capsules in Treating Postpartum Depression | Postpartum Depression | completed | 72 |
| 2025-08-08 | P3 | AbbVie ABBV | NCT03850782 Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | Open-Angle Glaucoma; Ocular Hypertension | completed | 515 |
| 2025-08-08 | P3 | Hoffmann-La Roche | NCT04961996 A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estr | Early Breast Cancer | active not recruiting | 4170 |
| 2025-08-08 | P3 | Eli Lilly and Company LLY | NCT05872620 A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Obesity; Overweight; Type 2 Diabetes | completed | 1613 |
| 2025-08-08 | P1/P2 | Sanofi SNY | NCT06508489 A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies | Acute Myeloid Leukemia | terminated | 7 |
| 2025-08-08 | P2 | Latigo Biotherapeutics LTGO | NCT06774625 This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars | Acute Pain, Postoperative | completed | 250 |
| 2025-08-10 est. | P2 | Xi'An Aolitai Pharmaceutical Technology Co Ltd | NCT06019936 A Randomized,Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MT2004 Capsule in DILI Subjects | Drug-Induced Liver Injury; Cholestatic Liver Injury; Mixed Liver Injury | unknown | 80 |
| 2025-08-11 | P1/P2 | Genmab GMAB | NCT05491317 A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors | Non-CNS Tumor | terminated | 13 |
| 2025-08-11 | P3 | Celgene | NCT06045806 A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adul | Multiple Myeloma | active not recruiting | 79 |
| 2025-08-11 | P2 | Chiesi Farmaceutici S.p.A. | NCT06900816 A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001 | Asthma | completed | 50 |
| 2025-08-11 | P3 | Colgate Palmolive CL | NCT06956599 Hypersensitivity Reduction Efficacy: 5% Potassium Nitrate Toothpaste Compared to Colgate Cavity Protection Toothpaste | Dentin Hypersensitivity | completed | 80 |
| 2025-08-12 | P2 | Merck Sharp & Dohme LLC MRK | NCT03742895 Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination D | Advanced Solid Neoplasms | active not recruiting | 329 |
| 2025-08-12 | P1/P2 | Clarion Cells, Inc. | NCT04631406 A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS) | Ischemic Stroke | active not recruiting | 27 |
| 2025-08-12 | P2 | Dr. Falk Pharma GmbH | NCT05621811 Different Doses of Naronapride vs. Placebo in Gastroparesis | Gastroparesis | completed | 328 |
| 2025-08-12 | P3 | AstraZeneca AZN | NCT06075095 A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Pr | COPD (Chronic Obstructive Pulmonary Disease) | completed | 297 |
| 2025-08-12 | P2 | Evergreen Therapeutics, Inc. | NCT07281105 EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study | Neuropsychiatric Systemic Lupus Erythematosus; Systemic Lupus Erythematosus (SLE); Cognitive Impairm | completed | 131 |
| 2025-08-13 | P2 | AL-S Pharma | NCT05039099 A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS | Amyotrophic Lateral Sclerosis | completed | 73 |
| 2025-08-13 | P3 | Boehringer Ingelheim | NCT05285982 A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON) | Lung Diseases, Interstitial | completed | 54 |
| 2025-08-13 | P2 | Novartis Pharmaceuticals NVS | NCT05384587 Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia - Chronic Phase | active not recruiting | 34 |
| 2025-08-13 | P2 | Noema Pharma AG | NCT06385795 A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause | Menopause Syndrome; Menopause; Hot Flashes | completed | 40 |
| 2025-08-13 | P3 | Innostellar Biotherapeutics Co.,Ltd | NCT07054632 Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations | Inherited Retinal Dystrophy Associated With RPE65 Mutations | active not recruiting | 30 |
| 2025-08-14 | P3 | Celgene | NCT04991935 Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis | Eosinophilic Esophagitis | completed | 367 |
| 2025-08-14 | P2 | Tvardi Therapeutics, Incorporated TVRD | NCT05671835 Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | completed | 100 |
| 2025-08-14 | P2 | Flamingo Therapeutics NV | NCT05814666 Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC | HNSCC | terminated | 69 |
| 2025-08-14 | P3 | Hanmi Pharmaceutical Company Limited HAFC | NCT06174779 A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus | Obesity | completed | 448 |
| 2025-08-14 | P3 | MoonLake Immunotherapeutics AG MLTX | NCT06411379 Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurati | Hidradenitis Suppurativa | completed | 418 |
| 2025-08-14 est. | P2 | PDFE Pharma Innovations FZCO | NCT07011485 A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia. | Alopecia, Androgenetic; Baldness; Androgenetic Alopecia (AGA) | active not recruiting | 15 |
| 2025-08-14 | P2 | Eli Lilly and Company LLY | NCT07085468 A Study of LY3549492 in Healthy Weight Adult Participants | Healthy | terminated | 1 |
| 2025-08-15 | P3 | AiCuris Anti-infective Cures AG | NCT03073967 Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised | HSV Infection | completed | 158 |
| 2025-08-15 | P3 | Teva Branded Pharmaceutical Products R&D LLC | NCT04530110 A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents | Migraine | completed | 499 |
| 2025-08-15 | P1/P2 | Erasca, Inc. ERAS | NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies | Metastatic Colorectal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma | completed | 101 |
| 2025-08-15 | P1/P2 | Dragonfly Therapeutics DFLI | NCT05597839 Study of DF9001 in Patients With Advanced Solid Tumors | Solid Tumor, Adult | completed | 24 |
| 2025-08-15 | P3 | BioXcel Therapeutics Inc BTAIQ | NCT05658510 Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) | Agitation,Psychomotor; Bipolar I Disorder; Bipolar II Disorder; Schizophrenia; Schizoaffective Disor | completed | 452 |
| 2025-08-15 | P3 | Organogenesis ORGO | NCT06000410 A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee | Knee Osteoarthritis | completed | 594 |
| 2025-08-15 | P1/P2 | Implicit Bioscience | NCT06275893 IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy | Arrhythmogenic Right Ventricular Dysplasia; Arrhythmogenic Left Ventricular Cardiomyopathy; Arrhythm | completed | 1 |
| 2025-08-15 | P2 | Beijing Wehand-Bio Pharmaceutical Co., Ltd | NCT06513364 Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer | Breast Cancer | completed | 40 |
| 2025-08-15 | P1/P2 | Seqker Biosciences, Inc. | NCT06614140 Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors | Cancer; Solid Tumor, Adult | completed | 8 |
| 2025-08-15 | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06671821 Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects | Chronic Weight Management | completed | 81 |
| 2025-08-16 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT04619433 A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC. | Non-squamous Non-small-cell Lung Cancer | terminated | 48 |
| 2025-08-17 | P3 | AstraZeneca AZN | NCT06168409 A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension | Resistant Hypertension | completed | 218 |
| 2025-08-18 est. | P3 | Biogen BIIB | NCT03637387 802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia | Trigeminal Neuralgia | withdrawn | |
| 2025-08-18 | P2/P3 | Recursion Pharmaceuticals Inc. RXRX | NCT05130866 Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas | Neurofibromatosis Type 2 | terminated | 25 |
| 2025-08-18 | P2 | ReveraGen BioPharma, Inc. | NCT05166109 A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD) | Becker Muscular Dystrophy | completed | 46 |
| 2025-08-18 | P3 | Laboratorios Sophia S.A de C.V. | NCT05217680 Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema | Diabetic Macular Edema | completed | 509 |
| 2025-08-18 | P2 | Akeso | NCT05247684 AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC | Resectable Non-small Cell Lung Cancer | active not recruiting | 90 |
| 2025-08-18 | P1/P2 | iOnctura | NCT05586516 A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer | Metastatic Pancreatic Cancer | completed | 16 |
| 2025-08-18 | P2 | Replimune, Inc. REPL | NCT05733611 RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | Refractory Metastatic Colorectal Cancer; pMMR; MSS | terminated | 5 |
| 2025-08-18 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT06139393 Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults | Gout With Hyperuricemia in Adults | completed | 765 |
| 2025-08-18 | P1/P2 | Genmab GMAB | NCT06171789 PRO1107 in Patients With Advanced Solid Tumors | Endometrial Cancer; Ovarian Cancer; Triple Negative Breast Cancer; GastroEsophageal Cancer; Non-smal | terminated | 33 |
| 2025-08-19 | P1/P2 | Lumicell, Inc. | NCT03834272 Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies | Peritoneal Metastases | completed | 18 |
| 2025-08-19 | P3 | Merck Sharp & Dohme LLC MRK | NCT04246177 Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With I | Carcinoma, Hepatocellular | terminated | 480 |
| 2025-08-19 est. | P3 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | NCT05913037 FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas | Neurofibromatosis 1; Plexiform Neurofibroma; NF1 | active not recruiting | 167 |
| 2025-08-19 | P3 | ACADIA Pharmaceuticals Inc. ACAD | NCT06173531 Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome | Hyperphagia in Prader-Willi Syndrome | completed | 175 |
| 2025-08-19 | P3 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | NCT06417281 Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid(5-ALA) | 5-aminolevulinic Acid; Malignant Glioma of Brain | completed | 86 |
| 2025-08-19 | P2 | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | NCT06854952 A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity | Overweight or Obesity | completed | 167 |
| 2025-08-19 est. | P2 | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | NCT06976177 Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis | Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis | recruiting | 310 |
| 2025-08-20 | P1/P2 | Celgene | NCT03374085 A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | Multiple Myeloma | terminated | 200 |
| 2025-08-20 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05815862 Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer | Advanced Lung Cancer; Ovarian Cancer | completed | 29 |
| 2025-08-20 | P1/P2 | Takeda TAK | NCT05886491 A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia | Leukemia | terminated | 16 |
| 2025-08-20 | P3 | Bayer | NCT05901831 A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Ch | Chronic Kidney Disease; Type 1 Diabetes Mellitus | completed | 242 |
| 2025-08-20 | P3 | Laboratorios Silanes S.A. de C.V. | NCT07328022 Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis | Bursitis; Tendinitis; Synovitis | completed | 89 |
| 2025-08-21 | P3 | Sanofi SNY | NCT06224348 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Bac | Dermatitis Atopic | completed | 643 |
| 2025-08-21 | P3 | ModernaTX, Inc. | NCT06602024 A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age | Seasonal Influenza | completed | 40805 |
| 2025-08-22 | P2 | Iovance Biotherapeutics, Inc. IOVA | NCT03108495 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma | Cervical Carcinoma | terminated | 210 |
| 2025-08-22 | P3 | Ionis Pharmaceuticals, Inc. IONS | NCT04849741 A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD) | Alexander Disease | active not recruiting | 54 |
| 2025-08-22 | P3 | AstraZeneca AZN | NCT04877691 Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | active not recruiting | 367 |
| 2025-08-22 | P3 | Hutchison Medipharma Limited | NCT05015608 Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification | Non-small Cell Lung Cancer | completed | 216 |
| 2025-08-22 | P2 | Biofrontera Inc. BFRI | NCT05080764 Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therap | Acne Vulgaris | completed | 120 |
| 2025-08-22 | P1/P2 | NiKang Therapeutics, Inc. | NCT05119335 A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma | ccRCC; Clear Cell Renal Cell Carcinoma; Kidney Cancer; Kidney Neoplasms; Renal Cancer; Renal Neoplas | terminated | 120 |
| 2025-08-22 | P3 | Calcilytix Therapeutics, Inc., a BridgeBio company | NCT05680818 Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 | Autosomal Dominant Hypocalcemia (ADH) | active not recruiting | 67 |
| 2025-08-22 | P2 | Beijing Joekai Biotechnology LLC | NCT05811442 Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease | Alzheimer's Disease | completed | 68 |
| 2025-08-22 | P2 | Crinetics Pharmaceuticals Inc. | NCT05907291 Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn) | Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia | completed | 38 |
| 2025-08-22 | P3 | Eli Lilly and Company LLY | NCT06045221 A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin | Type 2 Diabetes | completed | 1698 |
| 2025-08-22 | P3 | Lynk Pharmaceuticals Co., Ltd | NCT06276998 A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA) | Rheumatoid Arthritis | completed | 430 |
| 2025-08-22 | P3 | Wuhan YZY Biopharma Co., Ltd. | NCT06432296 Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody | Malignant Ascites | active not recruiting | 312 |
| 2025-08-23 est. | P1/P2 | Letolab | NCT06384235 Phase II Clinical Study of LTC004 in Patients With mCRC | Locally Advanced or Metastatic CRC | unknown | 30 |
| 2025-08-25 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT04305041 Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Mel | Melanoma | completed | 100 |
| 2025-08-25 | P1/P2 | Incyte Corporation INCY | NCT04370704 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignanc | Melanoma | completed | 61 |
| 2025-08-25 | P3 | AstraZeneca AZN | NCT05374512 A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are | Breast Cancer | active not recruiting | 644 |
| 2025-08-25 est. | P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT05688696 Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus, SLE | unknown | 186 |
| 2025-08-25 | P3 | Pfizer PFE | NCT05810038 A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects. | Migraine | completed | 787 |
| 2025-08-25 | P2 | Vaxcyte, Inc. PCVX | NCT05844423 Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants | Pneumococcal Vaccines | completed | 802 |
| 2025-08-25 | P1/P2 | BioNTech SE BNTX | NCT05988203 A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines | Monkeypox | completed | 96 |
| 2025-08-25 | P3 | Chongqing Claruvis Pharmaceutical Co., Ltd. | NCT06583486 A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar | Moderate to Severe Glabellar Lines | completed | 488 |
| 2025-08-25 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06644417 Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV | HBV Infection With LLV | completed | 122 |
| 2025-08-25 | P3 | Beijing Suncadia Pharmaceuticals Co., Ltd | NCT06723652 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous | Homozygous Familial Hypercholesterolemia | completed | 55 |
| 2025-08-25 | P3 | Qilu Pharmaceutical Co., Ltd. | NCT07081256 To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy. | Chemotherapy-Induced Nausea and Vomiting | completed | 665 |
| 2025-08-26 | P1/P2 | JW Pharmaceutical | NCT03055286 Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | Acute Myeloid Leukemia | terminated | 15 |
| 2025-08-26 | P3 | Eurofarma Laboratorios S.A. | NCT05118672 Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment | Cold; Flu Symptom | completed | 567 |
| 2025-08-26 | P3 | Otsuka Pharmaceutical Co., Ltd. | NCT05326347 A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia | Schizophrenia | completed | 247 |
| 2025-08-26 | P1/P2 | Selecxine | NCT05525247 A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination | Advanced Solid Tumor | terminated | 27 |
| 2025-08-26 | P2/P3 | Sutro Biopharma, Inc. STRO | NCT05870748 REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer | Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Platinu | terminated | 600 |
| 2025-08-26 | P3 | Regeneron Pharmaceuticals REGN | NCT06491914 A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic | Neovascular Age-Related Macular Degeneration; Diabetic Macular Edema | active not recruiting | 1126 |
| 2025-08-26 | P1/P2 | Inventprise Inc. | NCT06611371 Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age. | Group B Streptococcal Infections | active not recruiting | 600 |
| 2025-08-26 | P3 | InnoNext Sarl | NCT07031973 The Effect of Micronutrient Supplementation on Nutrition Status and Well-being | Micronutrient Deficiencies | completed | 150 |
| 2025-08-26 | P2 | Beijing Dayspring Pharmaceutical Technology Co., Ltd | NCT07076706 Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia | Male Pattern of Hair Loss, Androgenic Alopecia; Androgenetic Alopecia (AGA) | completed | 110 |
| 2025-08-26 | P3 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT07704684 Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine | Essential Hypertension | completed | 376 |
| 2025-08-27 est. | P3 | Saol Therapeutics Inc | NCT02616484 Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency: | Pyruvate Dehydrogenase Complex Deficiency | active not recruiting | 34 |
| 2025-08-27 | P3 | Janssen Research & Development, LLC | NCT04899336 A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Esch | Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention | completed | 17797 |
| 2025-08-27 | P3 | Pulnovo Medical (Wuxi) Co., Ltd. | NCT05824923 A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure | Pulmonary Hypertension; Heart Failure With Reduced Ejection Fraction; Hypertension; Vascular Disease | active not recruiting | 264 |
| 2025-08-27 | P3 | Nielsen BioSciences, Inc. | NCT05889845 Candin for the Treatment of Common Warts | Common Warts (Verruca Vulgaris) | completed | 330 |
| 2025-08-27 | P1/P2 | Hoffmann-La Roche | NCT05908786 A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma | Carcinoma, Hepatocellular | terminated | 62 |
| 2025-08-27 | P1/P2 | Sanofi Pasteur, a Sanofi Company SNY | NCT06128733 Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents | Meningococcal Immunisation; Healthy Volunteers | completed | 1215 |
| 2025-08-27 | P2 | LimmaTech Biologics AG | NCT06523231 Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants. | Shigellosis | completed | 110 |
| 2025-08-27 | P3 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | NCT06604624 Semaglutide in Treatment of Obesity | Weight Management | completed | 462 |
| 2025-08-28 | P2 | Mercator MedSystems, Inc. | NCT04858776 Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT | Iliofemoral; Thrombosis | active not recruiting | 60 |
| 2025-08-28 | P3 | Averitas Pharma, Inc. | NCT04967664 Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery | Post Surgical Neuropathic Pain | completed | 412 |
| 2025-08-28 | P1/P2 | Abcuro, Inc. | NCT05532722 ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) | T-cell Large Granular Lymphocytic Leukemia | completed | 21 |
| 2025-08-28 | P1/P2 | Cellcolabs Clinical SPV Limited | NCT06063590 A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients | Aging Frailty | completed | 12 |
| 2025-08-28 | P2 | PepGen Inc PEPG | NCT06079736 A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment | Duchenne Muscular Dystrophy | terminated | 7 |
| 2025-08-28 | P2 | Zenas BioPharma (USA), LLC ZBIO | NCT06564311 A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) | Relapsing Multiple Sclerosis | active not recruiting | 93 |
| 2025-08-29 | P3 | Harmony Biosciences Management, Inc. HRMY | NCT04977986 Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome | Fragile X Syndrome; Fragile X Syndrome (FXS) | completed | 257 |
| 2025-08-29 | P1/P2 | Kura Oncology, Inc. KURA | NCT04997902 Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | HNSCC | completed | 45 |
| 2025-08-29 | P1/P2 | Jazz Pharmaceuticals JAZZ | NCT05027139 A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer | HER2-expressing Cancers | completed | 52 |
| 2025-08-29 | P2 | Vedanta Biosciences, Inc. | NCT05370885 VE202 in Patients With Mild-to-Moderate Ulcerative Colitis | Ulcerative Colitis; Colitis, Ulcerative | terminated | 114 |
| 2025-08-29 | P3 | RHEACELL GmbH & Co. KG | NCT05464381 Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over) | Epidermolysis Bullosa | active not recruiting | 91 |
| 2025-08-29 est. | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05720026 Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer | HER2-positive Breast Cancer | unknown | 560 |
| 2025-08-29 | P3 | RHEACELL GmbH & Co. KG | NCT05838092 Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III) | Epidermolysis Bullosa | active not recruiting | 9 |
| 2025-08-29 est. | P2 | Keros Therapeutics, Inc. KROS | NCT05927012 A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemi | Iron Deficiency Anemia | withdrawn | |
| 2025-08-30 est. | P1/P2 | Binhui Biopharmaceutical Co., Ltd. | NCT03866525 OH2 Oncolytic Viral Therapy in Solid Tumors | Solid Tumor; Gastrointestinal Cancer | recruiting | 300 |
| 2025-08-30 | P2 | Jazz Pharmaceuticals JAZZ | NCT03929666 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocar | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract C | completed | 74 |
| 2025-08-30 est. | P1/P2 | Advanced Imaging Projects, LLC | NCT04469127 A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients. | Breast Cancer Stage IV | unknown | 100 |
| 2025-08-30 | P1/P2 | TCR2 Therapeutics | NCT05451849 A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Mesothelioma; Mesotheliomas Pleural; Mesothelioma, Malignant; Mesothelioma Peritoneum; Ovarian Cance | terminated | 14 |
| 2025-08-30 est. | P3 | Beijing Shenogen Biomedical Co., Ltd | NCT05594927 Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment | Hepatocellular Carcinoma | unknown | 261 |
| 2025-08-30 est. | P2 | BRIM Biotechnology Inc. | NCT05927428 Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis | Neurotrophic Keratitis | unknown | 12 |
| 2025-08-30 est. | P1/P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT06008366 A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors | Advanced Solid Tumor | unknown | 281 |
| 2025-08-30 est. | P1/P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT06008379 A Study of 7MW3711 in Subjects With Advanced Solid Tumors | Advanced Solid Tumor | unknown | 164 |
| 2025-08-30 est. | P1/P2 | Biocity Biopharmaceutics Co., Ltd. | NCT06055348 SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer | Serous Ovarian Cancer; Advanced Ovarian Cancer | unknown | 112 |
| 2025-08-30 est. | P3 | Chengdu Brilliant Pharmaceutical Co., Ltd. | NCT06339086 Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes | Type 2 Diabetes Mellitus | unknown | 478 |
| 2025-08-30 | P1/P2 | Evopoint Biosciences Inc. | NCT06558513 To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors | Advanced Tumor; Lymphoma | completed | 120 |
| 2025-08-30 | P2 | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | NCT06690242 MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease | Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis | completed | 115 |
| 2025-08-30 | P2 | CAGE Bio Inc. | NCT06810050 Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis | Atopic Dermatitis (AD) | completed | 180 |
| 2025-08-30 | P2 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | NCT07421232 A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia | Hypercholesterolemia and Mixed Hyperlipidemia | completed | 156 |
| 2025-08-31 | P3 | Autotelicbio | NCT05573477 Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes | Essential Hypertension; Diabetes Mellitus, Type 2 | completed | 255 |
| 2025-08-31 est. | P1/P2 | Renata PLC | NCT06531018 Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia. | Primary Immune Thrombocytopenia | recruiting | 100 |
| 2025-08-31 est. | P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06654440 A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy | Advanced Gynecological Malignancy | unknown | 100 |
| 2025-08-31 est. | P1/P2 | Beijing Anlong Biopharmaceutical Co., Ltd. | NCT06707753 Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD | Wet Age-related Macular Degeneration (wAMD) | active not recruiting | 21 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.